公开(公告)号：US12295966B2

公开(公告)日：2025-05-13

申请号：US18106138

申请日：2023-02-06

Applicant: The Australian National University ,  Griffith University

Inventor： Christopher Parish ,  Connor O'Meara ,  Lucy Coupland ,  Benjamin Ju Chye Quah ,  Farzaneh Kordbacheh ,  Anna Orlov ,  Anna Browne ,  Ross Stephens ,  Gregory David Tredwell ,  Lee Andrew Philip ,  Karen Knox ,  Laurence Mark von Itzstein ,  Chih-Wei Chang ,  Anne Brüstle ,  David Anak Simon Davis

IPC: A61K31/7028 ,  A61K31/7016 ,  A61P7/02 ,  A61P37/06

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

公开(公告)号：US20240109886A1

公开(公告)日：2024-04-04

申请号：US18263481

申请日：2022-01-28

Applicant: GRIFFITH UNIVERSITY

Inventor： Mark VON ITZSTEIN ,  Ibrahim EL-DEEB ,  Patrice GUILLON ,  Larissa HEILIG

IPC: C07D471/04 ,  A61P31/16 ,  C07D487/04 ,  C07D495/04

CPC classification number: C07D471/04 ,  A61P31/16 ,  C07D487/04 ,  C07D495/04

Abstract: The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection. (I) R3 is selected from the group consisting of:

公开(公告)号：US20230285529A1

公开(公告)日：2023-09-14

申请号：US17778739

申请日：2020-11-23

Applicant: GRIFFITH UNIVERSITY

Inventor： Michael GOOD ,  Danielle STANISIC ,  Ashwini Kumar GIDDAM ,  Aloysious SSEMEGANDA

IPC: A61K39/015 ,  A61P33/02 ,  A61K39/018

CPC classification number: A61K39/015 ,  A61P33/02 ,  A61K39/018 ,  A61K2039/55555

Abstract: Disclosed are compositions for stimulating a protective or therapeutic immune response to an apicomplexan parasite such as those from the Plasmodium or Babesia genus. More particularly, the compositions comprise a soluble parasite extract. The extract may be free of red blood cell components and/or contained in or associated with a particle such as a liposome. The compositions and methods disclosed herein are particularly useful in the prevention and treatment of parasitic diseases.

公开(公告)号：US20230187126A1

公开(公告)日：2023-06-15

申请号：US17924055

申请日：2021-05-07

Applicant: Griffith University

Inventor： Junwei Lu ,  Xiaokun Li

IPC: H01F30/16 ,  H01F27/30 ,  H01F27/26

CPC classification number: H01F30/16 ,  H01F27/306 ,  H01F27/263 ,  H01F2038/003

Abstract: A high-frequency rotary transformer, a machine and a high frequency transformer are defined that are simpler to manufacture and less expensive than existing transformers and machines. The high-frequency rotary transformer includes: a primary transformer core comprising a plurality of primary core elements, each defining a primary transformer winding portion; a secondary transformer core comprising a plurality of secondary core elements, each defining a secondary transformer winding portion; a primary winding associated with each of the primary core elements; and a secondary winding associated with each of the secondary core elements. The primary transformer core and the secondary transformer core together define a transformer core having a flux pathway linking the primary and secondary windings, and the primary transformer core and the secondary transformer core are configured to rotate relative to each other. A magnetic flux concentrator may be used to direct magnetic flux towards an inside of the rotary transformer.

公开(公告)号：US11638718B2

公开(公告)日：2023-05-02

申请号：US16884628

申请日：2020-05-27

Applicant: GRIFFITH UNIVERSITY

Inventor： Surendran Mahalingam ,  Lara Josefina Herrero

IPC: A61K31/737 ,  A61P19/02 ,  A61P31/14 ,  A61P29/00 ,  A61K9/00

Abstract: Disclose is a method of treating alphavirus infections, particularly in humans, in which pentosan polysulfate is administered to an infected subject. Whilst not effecting the viral load in a subject, the pentosan polysulfate acts to reduce inflammation in tissues, such as the muscles, and in the joints of a subject. In addition, cartilage damage in the joints may be reduced. The reduction in inflammation and/or cartilage damage acts to reduce the severe pain experienced by subjects suffering from alphavirus infections, such as Ross River virus, chikungunya virus and Barmah Forest virus.

公开(公告)号：US20220372459A1

公开(公告)日：2022-11-24

申请号：US17827072

申请日：2022-05-27

Applicant: GRIFFITH UNIVERSITY ,  THE UNIVERSITY OF ADELAIDE

Inventor： Michael Paul Jennings ,  Christopher Day ,  Adrienne Webster Paton ,  James Cleland Paton

IPC: C12N9/52 ,  C07K16/40 ,  G01N33/574

Abstract: A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having α2-3-linked N-glycolylneuraminic acid and glycans having α2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having α2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having α2-3-linked N-glycolylneuraminic acid.

公开(公告)号：US20220296857A1

公开(公告)日：2022-09-22

申请号：US17612955

申请日：2020-05-20

Applicant: GRIFFITH UNIVERSITY

Inventor： Andrew BULMER ,  Derek SMITH ,  Timothy SCOTT

IPC: A61M25/02 ,  A61M25/00

Abstract: A securement device for securement of a catheter connecting assembly to a body of a patient wherein the catheter connecting assembly includes two or more ports adapted to be coupled with the catheter, each port being formed by a respective port body wherein the ports are adapted to be fluidly coupled to a catheter hub of a catheter, the securement device comprising: a base having a continuous top surface and a continuous bottom surface wherein at least a portion of the top surface comprises an antimicrobial layer and wherein at least a portion of the bottom surface comprises an adhesive for attachment of the base to the body of the patient and wherein the base is dimensioned to prevent direct contact between said ports and body of the patient; and one or more retention formations located on the top surface of the base for receiving and retaining at least a portion of a housing comprising said one or more port bodies adapted to be coupled with a terminal end of the catheter.

公开(公告)号：US20220249907A1

公开(公告)日：2022-08-11

申请号：US17614208

申请日：2020-06-04

Applicant: Griffith University

Inventor： David Lloyd ,  Claudio Pizzolato ,  Dinesh Palipana ,  David John Saxby ,  Laura Elizabeth

IPC: A63B24/00 ,  A61N1/36 ,  A63B71/06 ,  A63B22/06 ,  G06F3/01 ,  G16H20/30 ,  G16H40/67

Abstract: The present invention relates to a rehabilitation system for rehabilitating a person with a neurological condition, such as a spinal cord injury (SCI). The system includes exercise equipment for enabling the person to exercise. One or more sensors are provided for sensing information from the person during exercise. The system also includes a model of the exercising person configured to receive the sensed information from the sensors and generate electrical stimulation for the person. Advantageously, the personalized computer model may be used to generate suitable electrical stimulation for the person, and avoid excessive stresses on the person which can lead to the fracturing of bones.

公开(公告)号：US11371033B2

公开(公告)日：2022-06-28

申请号：US16348732

申请日：2017-11-09

Applicant: GRIFFITH UNIVERSITY ,  THE UNIVERSITY OF ADELAIDE

Inventor： Michael Paul Jennings ,  Christopher Day ,  Adrienne Webster Paton ,  James Cleland Paton

IPC: C12N9/52 ,  C07K16/40 ,  G01N33/574 ,  A61K38/00

Abstract: A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having α2-3-linked N-glycolylneuraminic acid and glycans having α2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having α2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having α2-3-linked N-glycolylneuraminic acid.

公开(公告)号：US20210338685A1

公开(公告)日：2021-11-04

申请号：US17280603

申请日：2019-09-30

Applicant: Griffith University ,  Research Institute at Nationwide Children's Hospital

Inventor： Michael P. JENNINGS ,  Jennifer L. EDWARDS ,  Christopher J. DAY ,  Johnson MAK

IPC: A61K31/55 ,  A61K9/00 ,  A61K31/196 ,  A61K31/198 ,  A61P31/04 ,  A61P31/18

Abstract: The present disclosure relates to the use of ligands of complement receptor 3, including ligands of the I domain of the alpha subunit of this receptor, in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.